Covalent inhibitors of the common mutant isoform of RAS, KRAS(G12C), have begun to unlock the potential of targeting RAS oncoproteins, but limitations to this approach remain. Now, two papers ...
RAS(ON) Inhibitor Combination Studies: RMC-6236 with Pembrolizumab: RMC-LUNG-101B is an arm of the Phase 1b study of RMC-6236 in combination with pembrolizumab, with or without chemotherapy, in ...
REDWOOD CITY, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer ...
Tumor Regressions Observed During Combination Treatment with a Bi-Steric mTORC1-Selective Inhibitor and a KRAS G12C-Selective Inhibitor in Preclinical Lung Cancer Model that is Resistant to KRAS G12 C ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results